Mitchell, Shannon Gwin
Monico, Laura B.
Lertch, Elizabeth
Kelly, Sharon M.
Gryczynski, Jan
Jaffe, Jerome H.
O’Grady, Kevin E.
Schwartz, Robert P.
Funding for this research was provided by:
National Institute on Drug Abuse (2R01DA15842)
Article History
First Online: 13 March 2018
Compliance with Ethical Standards
:
: Dr. Schwartz in the past provided a one-time consultation to Reckitt-Benckiser, one of the manufacturers of buprenorphine, on behalf of Friends Research Institute. Dr. O’Grady in the past received reimbursement for his time from Reckitt–Benckiser. No financial disclosures were reported by the other authors.
: NIDA or the National Institutes of Health had no role in the design and conduct of the study; data acquisition, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.